Skip to main content

Advertisement

SpringerLink
Log in

Pharmacokinetic drug–drug interaction between olaparib and apixaban: a case report

  • Letter to the Editor
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Data Availability

All data generated or analyzed during this study are included in this published article.

References

  1. Farge D, Frere C, Connors JM, Khorana A, Kakkar A, Ay C et al (2022) 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol 23(7):e334–e347

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Use of anti-factor Xa levels in cancer patients taking direct oral anticoagulants. In: ISTH Congr. Abstr. https://abstracts.isth.org/abstract/use-of-anti-factor-xa-levels-in-cancer-patients-taking-direct-oral-anticoagulants/. Accessed 24 Feb 2023

  3. Delavenne X, Mismetti P, Basset T (2013) Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: application to pharmacokinetic study. J Pharm Biomed Anal 78–79:150–153

    Article  PubMed  Google Scholar 

  4. Mavri A, Vene N, Božič-Mijovski M, Miklic M, Soderblom L, Pohanka A et al (2021) Apixaban concentration variability and relation to clinical outcomes in real-life patients with atrial fibrillation. Sci Rep 11:13908

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Velev M, Puszkiel A, Blanchet B, De Percin S, Delanoy N, Medioni J et al (2021) Association between olaparib exposure and early toxicity in BRCA-mutated ovarian cancer patients: results from a retrospective multicenter study. Pharm Basel Switz 14:804

    CAS  Google Scholar 

  6. https://cancer-druginteractions.org/checker

  7. Pilla Reddy V, Bui K, Scarfe G, Zhou D, Learoyd M (2019) Physiologically based pharmacokinetic modeling for olaparib dosing recommendations: bridging formulations, drug interactions, and patient populations. Clin Pharmacol Ther 105:229–241

    Article  CAS  PubMed  Google Scholar 

  8. Deng F, Sistonen J, Neuvonen M, Niemi M (2023) Inhibition of efflux transporters by poly ADP-ribose polymerase inhibitors. Basic Clin Pharmacol Toxicol 133:428–436

    Article  CAS  PubMed  Google Scholar 

  9. Byon W, Garonzik S, Boyd RA, Frost CE (2019) Apixaban: a clinical pharmacokinetic and pharmacodynamic review. Clin Pharmacokinet 58:1265–1279

    Article  PubMed  PubMed Central  Google Scholar 

  10. Lafaie L, Hodin S, Saïb S, Bin S, Bertoletti L, Delavenne X et al (2022) Tyrosine kinase inhibitors and direct oral anticoagulants: in vitro evaluation of drug-drug interaction mediated by P-glycoprotein. Fundam Clin Pharmacol 36:860–868

    Article  CAS  PubMed  Google Scholar 

  11. Hanigan S, Das J, Pogue K, Barnes G, Dorsch M (2020) The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding. J Thromb Thrombolysis 49:636–643

    Article  CAS  PubMed  Google Scholar 

  12. Limcharoen S, Pongchaidecha M, Pimsi P, Limprasert S, Suphanklang J, Santimaleeworagun W et al (2022) Do apixaban plasma levels relate to bleeding? The clinical outcomes and predictive factors for bleeding in patients with non-valvular atrial fibrillation. Biomedicines 10:2001

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Author notes

  1. M. Berge and J. S. Giraud contributed equally to the work.

Authors and Affiliations

  1. Department of Clinical Pharmacy, Cochin University Hospital, Assistance Publique–Hôpitaux de Paris, CARPEM, 75014, Paris, France

    M. Berge, J. S. Giraud & A. Thomas-Schoemann

  2. Department of Medical Oncology, Cochin University Hospital, Assistance Publique–Hôpitaux de Paris, CARPEM, 75014, Paris, France

    S. De Percin

  3. Department of Pharmacokinetics and Pharmacochemistry, Cochin University Hospital, Assistance Publique–Hôpitaux de Paris, CARPEM, 75014, Paris, France

    A. Puszkiel & B. Blanchet

  4. Optimisation Thérapeutique en Neuropsychopharmacologie, Université Paris Cité, Inserm UMRS-1144, 75006, Paris, France

    A. Puszkiel

  5. Faculté de Pharmacie, Université Paris Cité, UMR8038 CNRS, U1268 INSERM, PRES Sorbonne Paris Cité, CARPEM, Paris, France

    A. Thomas-Schoemann & B. Blanchet

Authors
  1. M. Berge
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. S. Giraud
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. De Percin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Puszkiel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Thomas-Schoemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. B. Blanchet
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Berge.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Berge, M., Giraud, J.S., De Percin, S. et al. Pharmacokinetic drug–drug interaction between olaparib and apixaban: a case report. Cancer Chemother Pharmacol 93, 519–521 (2024). https://doi.org/10.1007/s00280-023-04606-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-023-04606-8

Search

Navigation